



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Franco Pamparana, et al.
Serial No: 09/869,333
Filed: July 26, 2001
For: ESSENTIAL FATY ACIDS IN THE PREVENTION OF
CARDIOVASCULAR EVENTS
Confirmation No: 5701
Art Unit: 1614
Examiner: Raymond J. Henley, III
Attorney Ref: FC-864/US
HDP Ref: 6794-000141/US/01
Pfizer Ref: 28532/US

November 22, 2004

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Madam/Sir:

To comply with 37 CFR §1.97 and §1.98, Applicants submit the enclosed Form PTO-1449 and copies of all documents listed on that form.

In accordance with MPEP §609 and §707.05(b), Applicants respectfully request that each document listed be given thorough consideration, and that the Examiner cite each document of record in the prosecution history of the present application by initialing Form PTO-1449 next to each document. Applicants request such initialing even if the Examiner does not consider: (1) a document to be sufficiently pertinent to use in a rejection; (2) a document to be prior art for any reason; or (3) that the guidelines for citation have been fully complied with respecting a particular document. Applicants make this request so that each document becomes cited on the face of a patent issuing on the present application.

Applicants submit this Information Disclosure Statement in compliance with the duty to disclose information material to patentability under 37 CFR §1.5, but by listing such documents are not admitting that such documents are necessarily relevant or prior art. Applicants intend no representation that the listed documents represent the results of a complete search. Applicants

Appl. No. 09/869,333
Information Disclosure Statement
November 22, 2004

anticipate that the Examiner, in the normal course of examination, will make an independent search consistent with 37 CFR §1.104(a) and §1.106(b), and, in the course of such search, will review for relevance every document listed on the attached form even if not initialed.

Applicants make no representation as to the accuracy of any translation provided with this Information Disclosure Statement.


Applicants request early and favorable consideration.

* * * * *

Applicants believe that they do not owe any fee in connection with this Information Disclosure Statement. If, however, Applicants do owe any such fee(s), the Commissioner is hereby authorized to charge the fee(s) to Deposit Account No. **08-0750**. In addition, if there is ever any other fee deficiency or overpayment under 37 C.F.R. §1.16 or §1.17 in connection with this patent application, the Commissioner is hereby authorized to charge such deficiency or overpayment to Deposit Account No. **08-0750**.

The Examiner is requested to call the undersigned if any questions arise that can be addressed over the phone to expedite examination of this application.

Respectfully submitted,




James E. Davis, PTO Reg. No. 47,516
Harness, Dickey & Pierce, P.L.C.
7700 Bonhomme, Suite 400
St. Louis, Missouri 63105
(314) 726-7500 (tel)
(314) 726-7501 (fax)

Appl. No. 09/869,333
Information Disclosure Statement
November 22, 2004

CERTIFICATE OF MAILING UNDER 37 CFR § 1.8

I certify that this correspondence is being deposited with the U.S. Postal Service on **November 22, 2004** with sufficient postage as first class mail (including Express Mail per MPEP § 512), and addressed to **Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450**.


Donna M. Tucker

JED/dmt

FORM HDP-1449 (Based on Form PTO-1449)

PATENT AND TRADEMARK OFFICE
INFORMATION DISCLOSURE CITATION
 (Use several sheets if necessary)

Sheet 1 of 1

ATTORNEY DOCKET NO.

SERIAL NO.

FC-864/US (6794-000141/US/01)

09/869,333

APPLICANT

Franco Pamparana, et al.

FILING DATE

GROUP

July 26, 2001

1614

U.S. PATENT DOCUMENTS

Ref. Desig.	Examiner's Initials	Document Number	Date	Name	Class/ Subclass	(If appropriate) Filing Date

FOREIGN PATENT DOCUMENTS

Ref. Desig.	Examiner's Initials	Document Number	Date	Country	Class/ Subclass	Translation Yes	No
1.		GB 2 221 843	02/21/1990	UK	A61K 31/20		

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

Ref. Desig.	Examiner's Initials	
2.		British National Formulary, No. 8, 1989, Chapter 2: Cardiovascular System, British Medical Association and the Royal Pharmaceutical Society of Britain
3.		Burr, et al., "Effects on Changes in Fat, Fish, and Fibre Intakes on Death and Myocardial Reinfarction: Diet and Reinfarction Trail (Dart)," The Lancet, 1989:757-761
4.		Burr, et al., "Diet and Reinfarction Trail (DART): Design, Recruitment, and Compliance," Europea Heart Journal, Vol. 10, 1989:558-567
5.		Luley, et al., "Bioavailability of Omega-3 Fatty Acids: Ethylester Preparations are as Suitable as Triglyceride Preparations," Akt. Ernähr. - Med., Vol. 15, 1990:123-125
6.		Norday, et al., "Absorption of the n-3 Eicosapentaenoic and Docosahexaenoic Acids as Ethyl Esters and Triglycerides by Humans ¹⁻³ ," American Society for Clinical Nutrition, Vol. 53, 1991:11-5-1190
7.		Schmidt, et al., "n-3 Fatty Acids: Prevention and Treatment in Vascular Disease," Bi & Gi Publisher, Verona - Springer Verlag, London, 1995
8.		Singh, et al., "Randomized, Double-Blind, Placebo-Controlled Trail of Fish Oil and Mustard Oil in Patients with Suspected Acute Myocardial Infarction: The Indian Experiment of Infarct Survival - 4," Cardiovascular Drugs and Therapy, Vol. 11, 1997:485-491
9.		GISSI-Prevenzione Investigators, "Dietary Supplementation with N-3 Polyunsaturated Fatty Acids and Vitamin E After myocardial Infarction: Results of the GISSI-Prevenzione Trial," The Lancet, Vol. 354, 1999:447-455
10.		Marchioli, et al., The Results of the GISSI-Prevenzione trial in the General Framework of Secondary Prevention," European Heart Journal, Vol. 21, 2000:949-952
11.		R. Marchioli, "Treatment with n-3 Polyunsaturated Fatty Acids After Myocardial Infarction: Results of GISSI-Prevenzione Trial," European Heart Journal Supplements, Vol. 3, 2001:D85-D97

Examiner:

Date Considered:

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

EL 961489627 US